|Dr. Kalamegam Gauthaman
Coordinator of Tissue Culture Service Unit
Tissue Culture & Regenerative Medicine Research Group
Dr. Kalamegam Gauthaman is an Associate Professor at the ‘Center of Excellence in Genomic Medicine Research, King Abdulaziz University. He graduated as a doctor (MBBS, India) and later received his doctoral degree from the National University of Singapore (PhD, Singapore).
His research expertise covers (i) the use of human embryonic stem cell (hESC) as a pharmaceutical screening tool for the study of potential drugs, their expansion in 2D/3D environments, their prolonged preservation, elimination of tumorigeneic (teratoma) potential; (ii) the derivation of human Mesenchymal stem cells (MSCs) from various sources (umbilical cord, bone-marrow, synovial tissue, dental pulp), their differentiation into useful tissues for the management of osteoarthritis, chronic non-healing skin ulcers, Alzheimer’s disease; (iii) evaluation of their anti-tumorigenic properties of stem cells against human primary cancers and cancer cell lines; and (iv) screening of phytochemicals (natural products) using physio-pharmacological assays on human tissue. He has won national and international competitive grants in the past and has successfully completed them. He has guided and trained 10 MSc and 3 PhD scholars leading to their award of respective degrees. To his credit he holds 01 patent (USA), 03 provisional patents (USA) and has published more than 60 research / review articles in peer reviewed scientific journals. He has also contributed to 07 book chapters and several international conference presentations.
The state-of-the-art tissue culture/stem cell facility at CEGMR is routinely involved in performing several in vitro assays (morphological, proliferation, cell cycle, cell death, protein expression, gene expression) related to physio-pharmacology, molecular biology, stem cell biology, cancer biology, nanotechnology and tissue engineering.
1. KACST grant titled, Human Wharton's Jelly stem cells (hWJSCs) and their putative role in ovarian cancer inhibition. Principal Investigator. 250 000.00 (USD). 2013.
2. KACST grant titled, Evaluation of human Wharton's jelly stem cells (hWJSCs) in the management of Alzheimer's disease. Principal Investigator. 500 000.00 (USD). 2013
1. Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions
Ali Mobasheri, Kalamegam Gauthaman, Giuseppe Musumecif, Mark E. Batt.
Maturitas 2014 78(3):188-98.
2. Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: a Knowledge-Driven Approach.
Kalamegam Gauthaman, Peter Natesan Pushparaj, Manoharan Rajeshkumar, Kothandaraman Narashimman, Mohammed Al-Qahtani1, Nam Sang Cheung, Jayapal Manikandan
CNS & Neurological Disorders - Drug Targets. 2014. 13 (2): 247-258.
3. Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice
Gauthaman K, Fong CY, Arularasu S, Subramanian A, Biswas A, Choolani M, Bongso A.
J Cell Biochem. 114(2):366-77. doi: 10.1002/jcb.24367.
4. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro.
Gauthaman K, Yee FC, Cheyyatraivendran S, Biswas A, Choolani M, Bongso A.
J Cell Biochem. 113(6):2027-39. doi: 10.1002/jcb.24073.
5. Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells.
Gauthaman K, Fong CY, Suganya CA, Subramanian A, Biswas A, Choolani M, Bongso A
Reprod Biomed Online. 24(2): 235-46. doi: 10.1016/j.rbmo.2011.10.007